Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
作者： Kami J. Maddocks , Amy S. Ruppert , Gerard Lozanski , Nyla A. Heerema , Weiqiang Zhao
DOI: 10.1001/JAMAONCOL.2014.218
关键词: Clinical trial 、 Chronic lymphocytic leukemia 、 Cancer 、 Cumulative incidence 、 Internal medicine 、 Acalabrutinib 、 Immunology 、 Discontinuation 、 Ibrutinib 、 Bruton's tyrosine kinase 、 Medicine 、 Oncology
摘要: … From this study, all patients initially assigned to ibrutinib therapy or who crossed over to ibrutinib therapy following progression of disease with ofatumumab were included. …
elsevier.com
sci-hub.se 参考文章(21)
Jan A. Burger, Michael J. Keating, William G. Wierda, Julia Hoellenriegel, Ghayathri Jeyakumar, Alessandra Ferrajoli, Stefan H. Faderl, Marylou Cardenas-Turanzas, Susan Lerner, Gracy Zacharian, Xuelin Huang, Hagop M. Kantarjian, Susan O'Brien, Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients Blood. ,vol. 122, pp. 675- 675 ,(2013) , 10.1182/BLOOD.V122.21.675.675
KR Rai, A Sawitsky, EP Cronkite, AD Chanana, RN Levy, BS Pasternack, Clinical staging of chronic lymphocytic leukemia. Blood. ,vol. 46, pp. 219- 234 ,(1975) , 10.1182/BLOOD.V46.2.219.219
Richard R. Furman, Zahra Asgary, John O. Mascarenhas, Hsiou-Chi Liou, Elaine J. Schattner, Modulation of NF-κB Activity and Apoptosis in Chronic Lymphocytic Leukemia B Cells The Journal of Immunology. ,vol. 164, pp. 2200- 2206 ,(2000) , 10.4049/JIMMUNOL.164.4.2200
Ingo Ringshausen, Folker Schneller, Christian Bogner, Susanne Hipp, Justus Duyster, Christian Peschel, Thomas Decker, Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cδ Blood. ,vol. 100, pp. 3741- 3748 ,(2002) , 10.1182/BLOOD-2002-02-0539
Sabine Ponader, Shih-Shih Chen, Joseph J. Buggy, Kumudha Balakrishnan, Varsha Gandhi, William G. Wierda, Michael J. Keating, Susan O'Brien, Nicholas Chiorazzi, Jan A. Burger, The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. ,vol. 119, pp. 1182- 1189 ,(2012) , 10.1182/BLOOD-2011-10-386417
Sarah E. M. Herman, Amber L. Gordon, Amy J. Wagner, Nyla A. Heerema, Weiqiang Zhao, Joseph M. Flynn, Jeffrey Jones, Leslie Andritsos, Kamal D. Puri, Brian J. Lannutti, Neill A. Giese, Xiaoli Zhang, Lai Wei, John C. Byrd, Amy J. Johnson, Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. ,vol. 116, pp. 2078- 2088 ,(2010) , 10.1182/BLOOD-2010-02-271171
Jason P. Fine, Robert J. Gray, A Proportional Hazards Model for the Subdistribution of a Competing Risk Journal of the American Statistical Association. ,vol. 94, pp. 496- 509 ,(1999) , 10.1080/01621459.1999.10474144
Richard R. Furman, Jeff P. Sharman, Steven E. Coutre, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian Flinn, Paolo Ghia, Herbert Eradat, Thomas Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Stephan Stilgenbauer, Paula Cramer, Maria Aiello, Dave M. Johnson, Langdon L. Miller, Daniel Li, Thomas M. Jahn, Roger D. Dansey, Michael Hallek, Susan M. O'Brien, Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. The New England Journal of Medicine. ,vol. 370, pp. 997- 1007 ,(2014) , 10.1056/NEJMOA1315226
Jennifer A. Woyach, Richard R. Furman, Ta-Ming Liu, Hatice Gulcin Ozer, Marc Zapatka, Amy S. Ruppert, Ling Xue, Daniel Hsieh-Hsin Li, Susanne M. Steggerda, Matthias Versele, Sandeep S. Dave, Jenny Zhang, Ayse Selen Yilmaz, Samantha M. Jaglowski, Kristie A. Blum, Arletta Lozanski, Gerard Lozanski, Danelle F. James, Jacqueline C. Barrientos, Peter Lichter, Stephan Stilgenbauer, Joseph J. Buggy, Betty Y. Chang, Amy J. Johnson, John C. Byrd, Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib The New England Journal of Medicine. ,vol. 370, pp. 2286- 2294 ,(2014) , 10.1056/NEJMOA1400029
John C. Byrd, Richard R. Furman, Steven E. Coutre, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Barbara Grant, Jeff P. Sharman, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Juthamas Sukbuntherng, Betty Y. Chang, Fong Clow, Eric Hedrick, Joseph J. Buggy, Danelle F. James, Susan O'Brien, Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia The New England Journal of Medicine. ,vol. 369, pp. 32- 42 ,(2013) , 10.1056/NEJMOA1215637